T
he novel hypotensive peptide, adre n omedullin (AM), was originally disc o v e red in human pheochro m o c ytoma (1). The major source of circ u l a t i n g AM is considered to be the vasculature (2), and this peptide may act as an antipro l i f e rative factor for vascular smooth muscle cells (3). Diabetes is characterized by longt e rm complications, including re t i n o p a t h y, n e p h ro p a t h y, and neuro p a t h y, all of which a re closely related to vascular damage; the role of AM in diabetes has been investigated in this context. Insulin secretion in the pancreas is inhibited by AM, an intravenous injection of which reduces the plasma insulin concentration (4). Hyperglycemia increases vascular AM expre s s i o n t h rough a protein kinase C (PKC)-dependent pathway (5). The issue of whether plasma levels of AM in diabetic patients with normal renal function are incre a s e d remains controversial (6) (7) (8) . When evaluating the relationship between plasma levels of AM and glucose, patients with re n a l i m p a i rment should be excluded, because plasma AM levels in those patients with mild renal insufficiency and serum cre a t inine levels of 1.34 ± 0.10 mg/dl are thre e times higher than those in control individuals (9). We examined whether or not plasma AM levels are related to clinical parameters, including levels of plasma glucose and HbA 1 c , in diabetic patients without nephropathy through the use of a new immunoradiometric assay (10).
A total of 77 diabetic patients (mean age 60.4 ± 1.3 years, 30 men and 47 women) and 15 healthy individuals (mean age 35.2 ± 3.7 years, 7 men and 8 women) p a rticipated in the study. Patients with s e rum creatinine levels 1.2 mg/dl, urin a ry protein that was positive according to the dip-stick test, or urinary albumin that was 30 mg/day were excluded. Blood samples were taken from the antecubital vein into chilled polypropylene tubes containing EDTA 2Na (1 mg/ml of blood) and a p rotinin (500 U/ml of blood) early in the m o rning after an overnight fast. Plasma was obtained by immediate centrifugation at 4°C and 3,000 rpm for 15 min. Plasma concentrations of AM were measure d using the AM RIA Shionogi kit (Osaka, Japan) (10).
Levels of plasma glucose and HbA 1 c i n the patients were significantly higher than those in control subjects (132.1 ± 5.3 vs. 86.9 ± 2.2 mg/dl, P 0.001 and 6.40 ± 0.17 vs. 4.92 ± 0.05%, P 0.001, re s p e ctively). There were no significant diff e rences in plasma AM levels, serum cre a t inine levels, mean blood pre s s u re, and BMI between the patients and control subjects (11.0 ± 0.3 vs. 10.6 ± 0.5 fmol/ml, 0.73 ± 0.02 vs. 0.70 ± 0.04 mg/dl, 90.8 ± 1.3 vs. 92.3 ± 2.9 mmHg, and 22.9 ± 0.3 vs. 23.0 ± 0.8 kg/m 2 , respectively). The AM plasma concentration in all participants was 10.9 ± 0.2 fmol/ml, which significantly correlated with the values for mean blood pre ss u re (r = 0.32, P 0.01) and BMI (r = 0.26, P 0.05) but not with those for age and levels of serum creatinine, plasma glucose, and HbA 1 c .
Hayashi et al. (6) re p o rted that plasma AM levels in patients with poorly contro l l e d diabetes are significantly higher than those in healthy volunteers and proposed that the elevated plasma AM level originates fro m vascular AM expression induced by hyperglycemia (5). However, two other gro u p s re p o rted that plasma AM levels are not a ffected by plasma glucose levels (7, 8) . The i n fluence of nephropathy must be excluded when evaluating the relationship between plasma levels of AM and glucose, because the plasma AM level is closely associated with renal function (9). The results of the p resent study showed that plasma AM levels and blood glucose controls do not s i g n i ficantly correlate in strictly selected patients without nephro p a t h y. Thus, it is likely that plasma AM levels are not dire c t l y a ffected by plasma glucose levels. However, vascular AM induced by hyperglycemia (5) may act as a local factor unless plasma levels of AM are increased. Ishimitsu et al. (11) suggested that the increased plasma AM level associated with essential hypert e n s i o n and chronic renal failure is involved in the defense mechanism against further blood p re s s u re elevation and/or body fluid re t e ntion (11). The significant corre l a t i o n between plasma AM levels and mean blood p re s s u re found in this study indicates that AM participates in this defense mechanism in diabetic patients. Assays in serum from nonfasting blood w e re undertaken for vitamin A as re t i n o l , vitamin E as -t o c o p h e rol standard i z e d against the total cholesterol level, vitamin C as ascorbate as previously described (3), and total antioxidant activity (TAA) as the f e rric reducing ability of plasma (FRAP) (4). The HbA 1 c n o rmal local range is 3.8-5.5%. Statistical analysis was achieved t h rough one-way analysis of variance followed by the unpaired Student' s t test, the 2 test, and multiple re g ression analysis.
T h e re were no significant diff e re n c e s between the groups in age, sex, and BMI. Diabetes duration (13.4 ± 11.1 vs. 8.3 ± 7.3 years, P 0.05) and smoking pre v a l e n c e (16 vs. 4%, P 0.001) were signific a n t l y higher among the Caucasian patients. Ve g etarianism was significantly more pre v a l e n t among the Indo-Asian patients (30 vs. 2%, P 0 . 0 0 1 ) . S i g n i ficant diff e rences between the g roups were found in levels of HbA 1 c , s e rum vitamin C, and serum vitamin A, but not serum vitamin E or TAA (Table 1) . In multivariate analysis, TAA was related to sex, but not age, smoking status, ethnicity, or HbA 1 c levels (P 0.05). When comparing Caucasian with Indo-Asian nondiabetic subjects, vitamin C levels were signific a n t l y lower in Indo-Asian patients, but their vitamin A levels were significantly higher. Caucasian patients had significantly lower vitamin C levels compared with Caucasian nondiabetic subjects. Among the IndoAsian patients, both vitamin C and vitamin A levels were significantly lower than in the c o n t rol Indo-Asian patients. No signific a n t d i ff e rences were found between the Caucasian and Indo-Asian patients. In multivariate analysis, which included analysis of age, sex, ethnicity, smoking status, vegetarian diet, and HbA 1 c levels as independent variables, vitamin C correlated with ethnicity and HbA 1 c levels (P 0.01), and HbA 1 c concentration alone was a significant variable for vitamin A (P 0.01). However, when the presence of diabetes is conside red as a variable, both vitamins corre l a t e to this (P 0.001), and the signific a n t e ffect of HbA 1 c concentration as an independent variable is lost.
Indo-Asian patients, as compare d with race-matched nondiabetic subjects, showed a significant reduction in levels of both vitamin C and vitamin A, and potential confounding factors did not relate to the observed diff e rences. Comp a red with their race-matched contro l g roup, Indo-Asian patients appeared to lose the potential protective effect of both vitamins, which may possibly contribute to enhanced vascular risk.
Low levels in the blood of both vitamin A and vitamin C are associated with an increased risk of cardiovascular disease (5,6), although vitamin A is not classifie d as an antioxidant. Recent studies have shown that the reduced circ u l a t o ry status of vitamin A in diabetic animals may be s e c o n d a ry to an impaired transport mechanism (7) and that the plasma concentrations of the carrier proteins of vitamin A, retinol-binding protein, and transthyre t i n , may be decreased in human diabetes (8). S i m i l a r l y, low vitamin C levels may be associated with the diabetic state itself (9), because an impairment in ascorbic acid metabolism and intracellular transport that is not correctable with dietary supplementation of vitamin C may exist (10).
The results suggest an association among ethnicity, diabetes, and antioxidant status that re q u i res further evaluation as a factor that determines potential risk of diff e rential diabetes-related vascular complications. Caucasian study population Indo-Asian study population C o n t ro l D i a b e t i c C o n t ro l D i a b e t i c p a t i e n t s p a t i e n t s p a t i e n t s p a t i e n t s P n 1 8 5 0 1 8 4 5 H b A 1 c ( % ) 4.5 ± 0.4 7.4 ± 1.5* 4.6 ± 0.4 6.9 ± 1.5 † 0 . 0 0 1 Vitamin C (µmol/l) 89 ± 26 60 ± 22* 66 ± 22 ‡ 53 ± 21 § 0 . 0 0 1 Vitamin A (µmol/l) 2.0 ± 0.9 1.8 ± 0.8 2.9 ± 1.6 ‡ 1.7 ± 0.7 † 0 . 0 0 1 Vitamin E (µmol/l) 22.7 ± 10.2 24.2 ± 9.7 21.9 ± 8.2 21.9 ± 7.8 N S FRAP (µmol [Trolox 551 ± 215 656 ± 327 571 ± 178 729 ± 364 N S e q u i v a l e n t ] )
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Data are means ± SEM. *P 0.001 vs. Caucasian control subjects; †P 0.001 vs. Indo-Asian contro l subjects; ‡P 0.01 vs. Caucasian control subjects; §P 0.05 vs. Indo-Asian control subjects. The Batista Pro c e d u re S i g n i fic a n t l y I m p roved Card i a c Function and Glycemic Control in a Diabetic Patient With Severe Insulin R e s i s t a n c e D e novo insulin resistance (IR) is a major metabolic defect in type 2 diabetes (1-3). In addition to this inherent defect, other temporary endogenous and exogenous factors result in various d e g rees of IR. Endogenous factors, such as catecholamines and glucocorticoids, are collectively re f e rred to as counterre g u l a t o ry h o rmones; exogenous factors include iatrogenic diabetogenic agents, such as stero i d s .
Catecholamines, and particularly norepinephrine, are produced in excessive amounts, both locally and systemically, during heart failure (4,5). In diabetic patients with advanced heart failure , glycemic control is difficult to attain, and, c o n s e q u e n t l y, re q u i rements for insulin or oral hypoglycemic agents are incre a s e d . H e a rt failure secondary to advanced dilated cardiomyopathy of various etiologies may become re f r a c t o ry to medical t h e r a p y, and effective surgical interv e n t i o n was, until re c e n t l y, limited to card i a c transplantation (6,7). The Batista pro c ed u re, which is a relatively new operation that involves a partial left ventriculectomy, was pioneered by Dr. Randas Batista in Brazil in the mid-1990s (8). Recent re l a t e d l i t e r a t u re provides the proven efficacy of this novel pro c e d u re to alleviate the crippling symptoms of advanced dilated cardiomyopathy (9-11).
It is logical to speculate that impro v i n g c a rdiac function and, thus, reducing circ ulating catecholamines would improve " t e m p o r a ry" IR in diabetic patients with s e v e re card i o m y o p a t h y. When medical therapy fails and the patient' s condition re q u i res cardiac transplantation, the Batista p ro c e d u re provides a valuable tre a t m e n t option to improve cardiac function. An additional advantage of the pro c e d u re is i m p roved glycemic control and incre a s e d insulin sensitivity.
We re p o rt here the case of a 54-yearold obese woman with long-standing i n s u l i n -requiring type 2 diabetes with insulin resistance. She had coro n a ry art e ry disease manifested by frequent angina and experienced episodes of acute heart failure on a weekly basis. In addition, she had class III cardiac symptoms, as defined by the New York Heart Association. Card i a c work-up revealed dilated ischemic thre evessel disease cardiomyopathy with ejection fraction (EF) of 15%. She was maximized on antifailure and anti-ischemic medical therapy, including furo s e m i d e , long-acting and sublingual nitrates, digoxin, and ACE inhibitors. Her sugar levels were controlled with administration of 100 U insulin daily; this dose was achieved with the use of tro g l i t a z o n e , administration of which lowered the initial insulin re q u i rements. She was considered a n o n s u rgical candidate for coro n a ry bypass because of advanced card i o m y o p a t h y. She was then re f e rred to a cardiovascular surgeon who trained under Dr. Batista, and he p e rf o rmed the combined Batista pro c e d u re and coronary bypass operation. The p a t i e n t ' s cardiac function improved dramatically after the operation. Symptoms related to heart failure and ischemia resolved, and EF improved to 35%. All of her medications were reduced or discontinued. Additionally, her insulin re q u i rements decreased by 5 0 % .
We believe that the patient achieved reduced levels of local and circ u l a t i n g catecholamines, resulting from impro v e d c a rdiac function that was brought about by surg e ry. This presumed reduction in c i rculating catecholamines, we believe, i m p roved glycemic control by re v e r s i n g t e m p o r a ry IR, a condition that re s u l t s f rom the counterre g u l a t o ry effects of these catecholamines. 
M a c rophage migration inhibitory factor (MIF) is re d i s c o v e red as a p ro i n fla m m a t o ry cytokine and gluc o c o rticoid-induced immunore g u l a t o r (1). We found that MIF was expressed in adipocytes, and that excretion of MIF protein could be induced by tumor necro s i s f a c t o r-( T N F -) stimulation (2).
Intere s ti n g l y, it has been re p o rted that the insulin s e c retion is regulated by the glucosedependent production of islet -cell MIF (3). According to this re p o rt, MIF mRNA e x p ression in the islet -cells is incre a s e d when they were incubated in higher glucose concentrations, and, more o v e r, islet MIF stimulates insulin secretion in a concentration-dependent manner. In this s t u d y, we examined the concentration of s e rum MIF in type 2 diabetes to clarify the possibility that MIF is associated with the d i s regulation of glucose metabolism.
In the current study, 79 patients with type 2 diabetes and 79 age-and sexmatched normal healthy control subjects p a rticipated. The characteristics of the subjects are shown in Table 1 . Informed consent was obtained from all subjects part i c ipating in this investigation. Of the 79 diabetic subjects, 30 were taking oral hypoglycemic agents, 32 were injecting human insulin, and 17 had diet therapy o n l y. Specialized ophthalmologists diagnosed the diabetic retinopathy and its clinical stage. The concentrations of serum MIF w e re measured according to a method previously described (2).
The content of serum MIF in type 2 diabetic patients was significantly high c o m p a red with that in normal contro l subjects, showing 20.7 ± 13.3 and 5.2 ± 3.0 ng/ml for type 2 diabetes and control subjects, respectively (P 0.0001) (Fig. 1 ). H o w e v e r, there was no correlation between the serum level of MIF and fasting plasma glucose, HbA 1 c , diabetes duration, and modes of diabetic therapy (Table 2) . T h e s e rum MIF level was elevated as the clinical stage of diabetic retinopathy advanced, but that was low in the proliferative stage ( F i g . 2). The serum MIF did not differ with the clinical stage of diabetic nephro p a t h y and neuro p a t h y.
The overe x p ression of TNF-in adipose tissue can induce peripheral insulin resistance. MIF protein secretion and MIF mRNA were detected in the rodent adipose tissue, and in cultured rodent adipocytes MIF secretion was increased by TNF-( 2 ) . Because MIF increases TNF-e x p re s s i o n and vice versa (3), increased serum MIF may cause insulin resistance in the adipose Table 1 -Clinical characteristics of study subjects Type 2 diabetes C o n t rol subjects P n 7 9 7 9 -Age (years) 53.8 ± 9.6 53.8 ± 9.6 N S Sex (M/F) 5 3 / 2 6 5 3 / 2 6 N S BMI (kg/m 2 ) 23.9 ± 2.9 23.8 ± 3.8 N S Mean blood pre s s u re (mmHg) 101 ± 13 103 ± 16 N S White blood cell count (/ml) 6,462 ± 1,809 6,077 ± 1,754 N S Red blood cell count ( 1 0 It should be noted that serum MIF content showed correlation with diabetic re t i n o p a t h y. TNF-and interleukin-1 (IL-1) play an important role in early diabetic retinopathy (6,7). In proliferative re t i n o p at h y, vascular epidermal growth factor and t r a n s f o rming growth factor-a re more essential. MIF induces the production of T N F -and IL-1 and they also induce the MIF production in the retina. We consider an elevated level of MIF in the early stage of diabetic retinopathy to re flect the enhancement of IL-1 and/or TNF-.
I n c reased serum MIF may be another n o n s p e c i fic marker for illness in general, rather than a key player in the pathogenesis of type 2 diabetes. In fact, MIF was i n c reased in the sera of patients with uveitis and atopic dermatitis (8,9). However, MIF has two biological effects: insulin secre t i o n and TNF-induction, and insulin re s i stance is closely related to inflammation. Further examination will be needed to know whether elevated serum MIF is associated with the pathogenesis of type 2 diabetes. Lamin A/C Mutation in a Woman and Her Two Daughters Wi t h D u n n i g a n -Type P a rtial Lipodystro p h y and Insulin R e s i s t a n c e T he lipodystrophies are a hetero g eneous group of disorders that are characterized by the complete or partial absence of adipose tissue, and they occur with a variety of clinical manifestations that include marked insulin re s i stance and diabetes (1). Patients with autosomal dominant Dunnigan-type familial partial lipodystrophy (FPLD) (OMIM 151660) are born with normal adipose tissue distribution, but, after pubert y, they experience adipocyte degeneration in their extremities, trunk, and gluteal region (1-4). Subjects with FPLD have insulin resistance before the development of diabetes, which is often associated with dyslipidemia and early coro n a ry heart disease (CHD). Recently, the FPLD gene was mapped to chromosome 1 q21-22 (1-4). This chromosomal segment harbors the LMNA gene, which encodes the nuclear s t ructural proteins lamin A and C (1-4). Mutations in LMNA w e re shown to underlie autosomal dominant-Emery -D re i f u s s muscular dystrophy (AD-EDMD), which is characterized by regional and pro g re s s i v e myocyte degeneration (5). We surm i s e d that the analogy between the re g i o n a l myocyte degeneration in AD-EDMD and the regional adipocyte degeneration in FPLD and its chromosomal position made LMNA a good candidate gene for FPLD.
The proband was a 56-year-old woman of nort h e rn European descent. She developed diabetes at the age of 30 years and was initially treated with oral hypoglycemic agents. At age 35, she presented with mild h y p e rtriglyceridemia and had biopsy-confirmed fatty infiltration of the liver. At that time, the clinical diagnosis of partial lipodys t rophy was made based on the characteristic clinical features, which included the absence of subcutaneous fat tissue from her upper and lower extremities, her extre m e l y muscular appearance, which commenced in adolescence, and the presence of excess adipose tissue in her face and neck, which gave her a pseudo-Cushingoid appearance.
Her glycemic control became pro g re ssively more difficult, and, at age 45, insulin therapy was initiated. At age 52, she underwent triple-vessel bypass coron a ry arterial grafting for unstable angina. She is presently treated with 30 U daily of human insulin with standard medications, including atorvastatin, for secondary prevention of CHD. Her 37-and 35-year-o l d daughters were each diagnosed with FPLD in their early twenties, based on their characteristic physical features, which were identical to those of their mother. Both daughters developed elevated plasma triglycerides in their early thirties. Both daughters had marked elevations of seru m insulin and C-peptide, both of which exceeded twice the upper limit of norm a l , although neither daughter is yet to be diagnosed as hyperg l y c e m i c .
Primers for DNA amplification and sequencing were derived using published sequence information for all 12 exons, all i n t ron-exon boundaries, and the 5 -and 3 -untranslated regions of LMNA ( 6 ). DNA sequencing revealed that the p roband was heterozygous for a G→A change at codon 482 in exon 8, which p redicted the replacement of arg i n i n e (CGG) by glutamine (CAG). A norm a l c o n t rol subject was homozygous for the wild-type sequence. We found no other LMNA coding or flanking sequence abnormalities. A rapid genotyping assay was then developed, which revealed that both daughters were heterozygous for the LMNA R482Q mutation, whereas the mutant allele was absent from 276 norm a l Caucasians (P 2.8 1 0 -7 ) .
These results strongly suggest that the LMNA R482Q mutation is the molecular basis for FPLD in these women. Lamin A and C are members of the intermediate filament multigene family. Both are absent f rom early embryos and undiff e re n t i a t e d cells but are present in most terminally diff e rentiated cells, including adipocytes. Lamin A and C form dimers through their rod domains and interact with chro m a t i n and integral proteins of the inner nuclear membrane through binding sites located in both the rod domain and in the 3 -t e rminal globular tail (6). The nonconserv ative LMNA R482Q change occurs within the 3 -t e rminal tail sequence that is common to both lamin A and C (6). The evol u t i o n a ry conservation of R482 acro s s human, mouse, rat, and chicken suggests that this residue is important for the normal function of lamin A and C (6). Given the strong genetic association of L M N A R428Q with FPLD, it now becomes i m p o rtant to demonstrate that other FPLD subjects also have LMNA m u t a t i o n s . A c k n o w l e d g m e n t s -This work was supp o rted by grants from MRC Canada (MT13430) and the Canadian Genetic Diseases N e t w o r k .
ROBERT
We thank Dr. A. Angel for re f e rring the study family to us and Dr. Jian Wang, Dore e n Jones, and Pearl Campbell for providing excellent technical assistance.
Novel concepts and materials derived fro m this work have been embodied in U.S. patent application C99-482 (17 September 1999). 
T
here are two subtypes in Japanese nonobese type 2 diabetic patients: one with normal peripheral insulin sensitivity and the other with primary peripheral insulin resistance (1,2). We recently showed that insulin resistance observed in nonobese Japanese type 2 diabetic patients is positively correlated with fasting triglyceride levels but not with BMI (3). There is a possibility that disturbed triglyceride metabolism is a preceding factor for the development of insulin resistance. In fact, it has already been reported that plasma glucose levels improve with administration of bezafibrate (4) and clofibrate (5) in type 2 diabetic patients, but the mechanism that triggers these improvements has yet to b e fully clarified. To understand the re l a t i o nship between insulin sensitivity and triglyceride metabolism, we examined 15 nonobese Japanese type 2 diabetic patients with hypertriglyceridemia (8 men a n d 7 women, aged 62.7 ± 2.0 years [mean ± SEM], BMI 23.7 ± 0.5 kg/m 2 , fasting triglyceride levels 150 mg/dl) before and after treatment of bezafibrate for 2 months. There were no changes in diet and medication before and during the examination (12 patients were tre a t e d with glibenclimide, but the same doses w e re continued), except for the administration of 400 mg/day of bezafib r a t e . The statistical analysis was perf o rm e d with the StatView 5 system (Statview, B e r k e l e y, CA).
After the treatment, fasting triglyceride levels significantly fell from 256 ± 32 to 134 ± 13 mg/dl (P 0.001). Fasting plasma glucose levels (162 ± 11 to 131 ± 7.0 mg/dl, P 0.01) and fasting insulin levels (10.8 ± 1.1 to 8.4 ± 0.7 µU/ml, P 0.05) also decreased signific a n t l y. Plasma H b A 1 c levels decreased, although not statistically significantly (7.6 ± 0.5 to 7.0 ± 0.3%, P = 0.19). To assess insulin sensitivi t y, we analyzed insulin resistance by using a homeostasis model assessment (HOMA-IR) (6), which provides a good corre l a t i o n with an insulin sensitivity index derived f rom a minimal model approach as pre v iously described (7, 8) . HOMA-IR levels s i g n i ficantly decreased from 4.1 ± 0.3 to 2.8 ± 0.3% after 2 months of therapy (P 0.01). Bezafibrate is an agent known to i n c rease the catabolism of very -l o w -d e n s i t y l i p o p roteins (9). Our present findings suggest that the improvement of triglyceride metabolism by bezafibrate lowers blood glucose levels by reducing insulin re s i stance and that elevated triglyceride levels a re the preceding factors for the development of insulin resistance in nonobese Japanese type 2 diabetic patients. 
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